论文部分内容阅读
Background Ceftriaxone/sulbactam (4:1) is a novel β-lactam/β-lactamase-inhibitor combination injection.A clinical study was designed to evaluate its efficacy and safety in the treatment of respiratory and urinary infections caused by ceftriaxone-resistant bacteria comparing with cefoperazone/sulbactam (2:1) on cefoperazone-resistant bacteria.